Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients.
AI Summary
Key Findings
Abstract
BACKGROUND AND OBJECTIVES: Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed. DESIGN, SETTING, PARTICIPANTS,&MEASUREMENTS: Nicotinic acid inhibits intestinal phosphate reabsorption and increases HDL cholesterol. This study tested the phosphate-lowering and HDL-increasing effect of Niaspan (prolonged-release nicotinic acid) in patients who were undergoing dialysis. Efficacy, safety, and tolerability of Niaspan were prospectively studied. Twenty dialysis patients, who were receiving a stable dosage of a calcium salt-containing drug for phosphate control, received after a 2-wk washout period Niaspan for 12 wk. Patients were started on 375 mg/d, and the dosage was increased every 2 wk to achieve 500, 1000, 1500, and 2000 mg/d, respectively. Clinical and laboratory parameters were prospectively recorded in patients who tolerated a target dosage of>or = 1000 mg/d. RESULTS: Seventeen patients tolerated>or = 1000 mg/d Niaspan (mean dosage 1470 +/- 110 mg/d). Niaspan treatment for 12 wk decreased serum phosphate values from 7.2 +/- 0.5 to 5.9 +/- 0.6 mg/dl (P
Affiliation
Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charité, HELIOS-Klinikum-Berlin, Berlin, Germany.
External References
- PubMed ID:
- 17913971
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.